Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

  1. Cabrero, M.
  2. Martin, A.
  3. Briones, J.
  4. Gayoso, J.
  5. Jarque, I.
  6. López, J.
  7. Grande, C.
  8. Heras, I.
  9. Arranz, R.
  10. Bernal, T.
  11. Perez-Lopez, E.
  12. López-Godino, O.
  13. Conde, E.
  14. Caballero, D.
Revista:
Biology of Blood and Marrow Transplantation

ISSN: 1523-6536,  1083-8791

Any de publicació: 2017

Volum: 23

Número: 1

Pàgines: 53-59

Tipus: Article

DOI: 10.1016/J.BBMT.2016.10.003 GOOGLE SCHOLAR lock_openAccés obert editor

Objectius de Desenvolupament Sostenible

Font de les dades: Scopus